摘要
目的评价美罗培南(meropenem,MEM)对非结核分枝杆菌(non-tuberculous mycobacteria,NTM)的体外抑菌效果。方法收集首都医科大学附属北京胸科医院2015年1月至2016年12月分离的NTM临床分离株,共计207株。采用微孔板AlamarBlue法测定MEM对纳入的207株NTM临床分离株的体外抑菌效果。同时,评价其对46种NTM标准株[30株快生长分枝杆菌(rapidly growing mycobacterium,RGM)和16株慢生长分枝杆菌(slowly growing mycobacterium,SGM)]的体外抑菌情况。结果在30株RGM标准菌株中,26.7%(8/30)的菌种对MEM耐药。MEM对偶发和脓肿分枝杆菌临床分离株的耐药率分别为33.3%(11/33)和82.5%(33/40)。在16株SGM标准株,56.3%(9/16)的菌株对MEM耐药。在SGM临床分离株中,MEM对戈登分枝杆菌、胞内分枝杆菌、鸟分枝杆菌和堪萨斯分枝杆菌的耐药率分别依次为20.0%(2/10)、63.9%(23/36)、72.7%(16/22)和95.6%(43/45)。结论MEM对于大多数RGM菌种和部分SGM菌种都显示出一定的体外抑菌活性,其中对偶发分枝杆菌和戈登分枝杆菌则显示出相对较好的体外抑菌活性。
Objective The main goal of this study was to evaluate the in vitro inhibitory activity of meropenem against non-tuberculous mycobacteria (NTM).Methods Alamar Blue Assay was performed with micro-well plate to determine the Minimal Inhibitory Concentrations (MICs) of 207 NTM strains against meropenem. The strains consisted of different NTM species and were isolated from January 2015 to December 2016 in Beijing Chest Hospital, Capital Medical University. Furthermore, 46 reference strains were also tested, which included 30 rapidly rowing mycobacterium (RGM) species and 16 slowly growing mycobacterium(SGM) species.Results Among the 30 tested RGM species, 26.7%(8/30) were resistant to meropenem. The meropenem resistant rates of clinical isolates of M.fortuitum and M.abscessus were 33.3%(11/33) and 82.5%(33/40), respectively. Meropenem exhibited moderate activities against SGM species. Among the 16 tested SGM species, 56.3%(9/16) were resistant to meropenem. The meropenem resistant rates of clinical isolates of M.gordonae, M.intracellulare, M.avium and M.kansassii were 20.0%(2/10), 63.9%(23/36),72.7%(16/22), and 95.6%(43/45), respectively. Conclusion This study demonstrated that meropenem had inhibitory activities against the majority RGM species and some SGM species in vitro, while had relatively better inhibitory activities against M.gordonae and M.fortuitum.
作者
于霞
罗晶晶
赵立平
徐洋
梁倩
马异峰
董玲玲
黄海荣
YU Xia;LUO Jing-jing;ZHAO Li-ping;XU Yang;LIANG Qian;MA Yi-feng;DONG Ling-ling;HUANG Hai-rong(National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing 101149, China)
出处
《中国防痨杂志》
CAS
CSCD
2019年第3期302-307,共6页
Chinese Journal of Antituberculosis
基金
北京市医院管理局重点医学专业发展计划(ZYLX201824).
